Although there have been plenty of PET tracers for the imaging of tumor angiogenesis reported and wildly used in clinical in recent years, none of which have been implemented in international guidelines, in spite of these tracers possess great potential in detecting EGFR status in vivo and personalizing therapies for NSCLC patients. This evidence concerns the gene EGFR and neoplasm.